ライフサイエンスコーパス: washout period

1 ose interval and a final dose after a 2-week washout period).

2 ebo or PF-04958242 for 5 days separated by a washout period.

3 g two 16-wk diet periods separated by a 4-wk washout period.

4 8-d dietary periods were separated by a 28-d washout period.

5 Response returned to baseline within a 2-min washout period.

6 turned for a final visit after a 4-week drug washout period.

7 at the second baseline visit after a 2-week washout period.

8 aseline, after supplementation, and during a washout period.

9 73), or placebo (n=71), followed by a 4 week washout period.

10 y rigorous daily toothbrushing over a 4-week washout period.

11 The trials were separated by a 2-wk washout period.

12 treatment period with a minimum of an 8-week washout period.

13 tient underwent 2 ETTs separated by a 1-week washout period.

14 omized 5-week crossover design with a 5-week washout period.

15 ominent eosinophilic inflammation during the washout period.

16 eatment lasted 7 d and was followed by a 7-d washout period.

17 by the alternative dosage form after a 72-hr washout period.

18 olic acid and placebo separated by an 8-week washout period.

19 (n = 5 in each group), followed by an 8-week washout period.

20 fedipine treatment was retained during a 4 d washout period.

21 ch, in a random order, separated by a 4-week washout period.

22 -min constant infusion followed by a 110-min washout period.

23 ek treatment period, separated by a two-week washout period.

24 sion period and during a 45-minute adenosine washout period.

25 pentylxanthine, abolished the PAE during the washout period.

26 thin 6% of baseline in both groups after the washout period.

27 from rice and seafood following a three-day washout period.

28 at weeks 4, 8, and 12; and at the end of the washout period.

29 to receive the other regimen after a 1-week washout period.

30 function in the montelukast group after the washout period.

31 ame dosage as their prestudy regimen with no washout period.

32 y a 3-d placebo, and was separated by a 12-d washout period.

33 as followed by a 6-week single-blind placebo washout period.

34 ne if changes were sustained during a 4-week washout period.

35 he 2 assessments were separated by a 6-month washout period.

36 ly consumed for 2 wk and separated by a 4-wk washout period.

37 that were separated by a 14-d habitual diet washout period.

38 switched to the other TNF inhibitor with no washout period.

39 r US diet for 24 d each, separated by a 28-d washout period.

40 intervention periods separated by an 8-week washout period.

41 daily) in random order separated by a 2 week washout period.

42 ) twice daily for 6 months after a screening washout period.

43 ven sequentially for 50 d followed by a 50-d washout period.

44 ssed over to another treatment after an 8-wk washout period.

45 treatment period was separated by a 3-4 week washout period.

46 intervention phases were separated by a 14-d washout period.

47 3-month treatment period and after a 1-month washout period.

48 These effects persisted after a 6-week washout period.

49 were monitored throughout the treatment and washout period.

50 h to the other study AI after a 2- to 8-week washout period.

51 dine (IdU) for 30 days, followed by a 40-day washout period.

52 ir regular medication, followed by a 12-week washout period.

53 ntal Mg/d) or a placebo for 4 wk with a 1-mo washout period.

54 440 microg of FP daily, separated by 2-week washout periods.

55 Treatment periods were separated by 6-wk washout periods.

56 -DASH diet) for 3 wk each, separated by 2-wk washout periods.

57 ree 10-week treatment periods and two 6-week washout periods.

58 -wk duration were provided separated by 2-wk washout periods.

59 periods was randomized with at least 2-week washout periods.

60 ll 5 doses with each dose separated by >2-wk washout periods.

61 bilastine daily each for 7 days with 14-day washout periods.

62 After a washout period, 12 of the subjects entered a randomized,

63 s, and 12 months and after a further 2-month washout period (14 months).

64 3-wk run-in periods and separated by a 5-wk washout period, 20 healthy subjects (7 men and 13 women)

65 golimod treatment may happen even with short washout periods (4 weeks) and may perpetuate despite ste

66 n (1.5-2 MBq/liter) for 8 min, followed by a washout period (50 min).

67 After a 24-hr washout period, a single oral dose of ketoconazole (400

68 itching to the other TNF inhibitor without a washout period after insufficient primary response to th

69 witching to a second TNF inhibitor without a washout period after primary failure to a first TNF inhi

70 After a washout period, all of the subjects received a one-time

71 After a washout period, all of the subjects received red wine, t

72 After a medication washout period, all patients received intravenous epopro

73 After a washout period, all subjects received RW (30 g alcohol/d

74 y assigned in a crossover trial, and after a washout period, all subjects received RW, dealcoholized

75 essant benefit of treatment after the 4-week washout period, although somatic complaints increased in

76 control cereals for 6 wk, followed by a 6-wk washout period and a 6-wk crossover treatment period.

77 f raltegravir 400 mg on day 10 followed by a washout period and a single dose of raltegravir 400 mg o

78 BP) concentrations were determined after the washout period and after each of the treatments, and cha

79 ons were noted to persist following a 3-week washout period and corresponding restoration of circadia

80 ntly activated Notch followed by a prolonged washout period and observed that, in addition to decreas

81 s were crossed over to the other arm after a washout period and repeat baseline symptom assessment.

82 the first intervention, followed by a 3 day washout period and then 5 days with the other interventi

83 bo for three months, followed by a one-month washout period and then by three months of therapy with

84 or placebo for 4 weeks followed by a 2-week washout period and then crossover to the alternate treat

85 8 weeks, after which they underwent a 2-week washout period and then received the alternative regimen

86 therapy for 4 weeks, followed by a 2-4 week washout period and then the other intervention for 4 wee

87 to 0.9 mg/d whose symptoms returned during a washout period and who returned for at least the week 20

88 eek oral lead-in phase, followed by a 1 week washout period and, after safety assessment, three intra

89 y placebo for 8 weeks, followed by a 2-week "washout period" and then 8 weeks of the alternative trea

90 After dietary stabilization, a 2- to 12-week washout period, and a 4-week, single-blind, placebo lead

91 2-mg oral dose, followed by a minimum 14-day washout period, and subsequent coadministration of a sin

92 00-mg oral dose, followed by a minimum 8-day washout period, and subsequent coadministration of a sin

93 oric period of 2 weeks, followed by a 6-week washout period, and then again during a hypercaloric 2-w

94 wice daily for 70 days, followed by a 14-day washout period, and then placebo for 70 days, or the stu

95 t exclude patients on the basis of a placebo washout period, and they used the Hamilton Depression Ra

96 odide) remained in the tumors after the 24-h washout period, and this fraction varied between the dif

97 30 m, 1 day at 2590 m, separated by a 2-week washout period at less than 800 m.

98 irheumatic drugs (DMARDs) for an appropriate washout period (at least 1 month) and who, after the was

99 A 5-day washout period before CABG was recommended for patients

100 The mean washout period before the initiation of fingolimod was 2

101 This was followed by a 4-wk washout period before volunteers crossed to the alternan

102 erol were assessed after a 2-wk beta-agonist washout period, before administering study medication on

103 ents for 10 wk, and then went through a 4-wk washout period, before switching to the other treatment

104 twice weekly, each for 4 weeks with a 1 week washout period between crossover.

105 tment periods lasted 4 months with a 1-month washout period between diets.

106 administered in a random order with a 28-day washout period between infusions.

107 y, 3 days per week for 1 week, with a 1-week washout period between the 2 treatment weeks.

108 cebo, twice daily for 4 weeks, with a 2-week washout period between treatments.

109 nistered in a crossover fashion with a 7-day washout period between treatments.

110 2 mg isoflavones/d for 17 d each with a 25-d washout period between treatments.

111 ebo twice daily for a month, with a one-week washout period between treatments.

112 orally in a crossover fashion after a 2-week washout period between treatments.

113 a single-blind crossover design with a 2-wk washout period between treatments.

114 /d) or placebo (n = 22) for 8 wk with a 4-wk washout period between trials.

115 night) sleep conditions for 3 d, with a 4-wk washout period between visits.

116 seline period and intervening 2-week placebo washout periods between treatments.

117 A 7-day washout-period between trial periods was used.

118 10 and 50 nM) for 30 min, and after a 60-min washout period, concentration-response curves were deter

119 A as food energy for 4 wk and, after a 10 wk washout period, consumed a 15% PUFA diet for another 4 w

120 ries from total fat) for 28 d with a >/=2-wk washout period.Consumption of the cashew diet resulted i

121 t, low-fiber diet for 10 wk and after a 2-wk washout period crossed over to the other diet.

122 nitive deficits persisted even after a 3-day washout period during the third phase.

123 ent was followed by a two-week, single-blind washout period during which all patients received placeb

124 ed for a 10-week period followed by a 2-week washout period during which patients were bathed with no

125 reatment periods were separated by a 3-month washout period, during which patients received on-demand

126 After a 14-day washout period, each patient then received 776C85 daily

127 2.5 mg/kg MPD was given, followed by a 4-day washout period (ED 15 -18).

128 ys (from ED 9 to ED 14), followed by a 3-day washout period (ED 15 to ED 18).

129 After a 4-week washout period, eligible patients had the option to swit

130 l of benzodiazepine treatment, followed by a washout period, exacerbated memory impairment in AD tran

131 After a 5-day washout period, five patients received 5 mg apixaban twi

132 , Rockville Centre, NY) followed by a 1-week washout period followed by 4 weeks of a placebo lubricat

133 A 4-week washout period followed the 12-week treatment phase.

134 of colchicine, separated by a minimum 14-day washout period, followed by administration of the approv

135 After a washout period >/= 4 wk, subjects received an intravenou

136 period (at least 1 month) and who, after the washout period, had a stable joint count (at least 10 te

137 1 and 4 days of treatment, and after a 6-day washout period, hypothesizing dose-dependent decreases i

138 ment in a 3 x 3 crossover design with a 1-wk washout period in between treatments.

139 steroid for 1 to 2 weeks with a 1- to 2-week washout period in between.

140 00 mg BID for 14 days, or vice-versa, with a washout period in between.

141 randomized Latin square design study with a washout period of >/=14 d was conducted.

142 Each diet was consumed for 4.5 wk, with a washout period of >/=2 wk between diet phases.

143 After the washout period of >/=28 d, the same participants consume

144 s who each completed 5 visits with a minimum washout period of 1 wk between testing days.

145 After a washout period of 1 wk, the protocol was repeated with a

146 After a washout period of 10-15 wk, the subjects were fed the al

147 ional treatment for 26 weeks, separated by a washout period of 17 weeks.

148 005% were studied separately, with a minimum washout period of 2 weeks between studies.

149 p) or without (continuous treatment group) a washout period of 20 weeks.

150 and valsartan (160 mg/d) for 7 days, with a washout period of 3 weeks in between the treatments.

151 After a washout period of 3 weeks, subjects were switched to the

152 After a washout period of 4 months, the subjects consumed the sa

153 dextrin placebo 3 times/d (HFr); there was a washout period of 4 to 10 wk between each condition.

154 ring wash-in period of 20 min, followed by a washout period of 40 min.

155 o cereal bars were consumed for 8 wk, with a washout period of 8 wk between the crossover.

156 of olive oil alone for 24 wk, followed by a washout period of 8 wk, and then the alternative capsule

157 y protein/d) diets for 1 week, followed by a washout period of at least 2 weeks.

158 or a typical Australian diet, followed by a washout period of at least 21 days, before crossing over

159 reatment periods were separated by an active washout period of at least 9 weeks.

160 r 3 hours daily for 5 months, with a 1-month washout period of no patching before the 6-month primary

161 s were consumed in random order separated by washout periods of > or =2 wk.

162 rage, 9.2, 22.5, 46.3 and 91 mg . d(-1) with washout periods of 2 wk between each intake.

163 ions in random sequence: (1) after a 27-hour washout period (Off-BB) and (2) 3 hours after beta-block

164 After a minimum 7-day washout period, participants began taking one 300-mg tab

165 Following a 2-week washout period, participants crossed over to the alterna

166 Following a 4-week washout period, participants crossed over to the other t

167 After a 2-week washout period, participants in each group received the

168 After a 3-week, single-blind placebo-washout period, participants were randomized to diet and

169 /kg orally every 3 days followed by a 1-week washout period), patients were crossed over to the alter

170 After a 2-10-day drug washout period, patients began treatment with clozapine

171 After a washout period, patients crossed over for an additional

172 After a 1-week washout period, patients crossed over to treatment B (pl

173 After a washout period, patients meeting entry criteria were ran

174 After a 2-day washout period, patients were re-treated with VX-710 on

175 After a washout period, patients were then crossed over to the a

176 After a second washout period, patients were treated with 776C85 daily

177 A 6-wk washout period separated the treatment periods.

178 After a 10- to 21-day washout period, subjects crossed over to either placebo

179 After a 2-week washout period, subjects received the alternate treatmen

180 Medication conditions were separated by a washout period that was 7 days.

181 After a washout period, the hemodynamic effects of this infusion

182 After a 60-min washout period, the other mask was applied.

183 Following a washout period, the procedure was repeated with the alte

184 wice daily, or placebo for 8 weeks, a 2-week washout period, then the alternative therapy for 8 weeks

185 After a 3-7 day-placebo washout period, there was a 4-week, double-blind, fixed-

186 After a washout period, they crossed over to the alternate thera

187 Following a 90-day washout period, they were treated for 90 days with the o

188 the effect, followed by a randomised 4-week washout period to assess withdrawal effects.

189 nsitized state that requires an agonist-free washout period to recover.

190 Following a minimum 7-day washout period (until the symptoms induced by the previo

191 A 3-week washout period was implemented between the interventions

192 , FTHA infusion was terminated, and a 15-min washout period was observed.

193 Washout periods were 2-4 wk for both groups.

194 l syndromes should avoid somatostatin analog washout periods when possible and should include quality

195 ment (primary outcome) and during the 2-week washout period with the use of mixed-effects regression

196 ts undertook the alternate diet after a 2-wk washout period, with results compared after the diet per

197 min, and this step was followed by a 20-min washout period without tracer in the perfusion medium.

198 ab treatment, duration and management of the washout period (WP), and relapse or adverse events durin